ASCO 2024: KN426 and the CLEAR trial - Tissue-Based Biomarkers for Kidney Cancer

Toni Choueiri and Brian describe similarities and differences in the biomarker findings of the KN426 and CLEAR trials, leading to debate about the value and future of their treatment approaches.